Press Releases
Search
-
28 Sep 2011
Mise en œuvre du retrait obligatoire visant les actions AES Chemunex
Marcy L'Etoile, France - September 28, 2011. Communiqué de mise à disposition de la note d’information de bioMérieux et de la note en réponse d’AES Chemunex visées par l’AMF, ainsi que des information...
-
06 Sep 2011
bioMérieux - First-Half Results at June 30, 2011
Marcy L'Etoile, France - September 6, 2011. Operating income before non-recurring items Up 5.2% At 17.8% of sales Two strategic acquisitions: AES Laboratoire, making bioMérieux world leader in food te...
-
06 Sep 2011
bioMérieux - First-Half 2011 Business Review
Marcy L'Etoile, France - July 19, 2011. At constant exchange rates and comparable business base* First-half sales up 4.3% Second-quarter sales accelerate: up 5.1% Good performance in North America con...
-
27 Jul 2011
New Study Reports: CancerTYPE ID Expands Tumor Type Coverage and Demonstrates Clinical Utility - CancerTYPE ID is Now a Covered Benefit for Medicare Part B Patients
SAN DIEGO, Calif., - July 27, 2011. bioTheranostics, a bioMérieux company that develops innovative oncology diagnostic tests to support targeted disease management, announced today study results publi...
-
22 Jul 2011
Completion of the AES Chemunex group acquisition and filing of a tender offer for the AES Chemunex shares
Marcy-l’Etoile, France - July 22, 2011. bioMérieux has today acquired the entire capital and voting rights of Skiva (441 886 728 R.C.S. Paris), the parent company of the AES Chemunex group. Through th...
-
19 Jul 2011
bioMérieux Expands its Infectious Disease Offering with Acquisition of ARGENE, Specialized in Molecular Diagnostics for Immunocompromised Patients
Marcy l'Etoile, France - July 19, 2011 . bioMérieux, a world leader in the field of in vitro diagnostics, announced that it has acquired ARGENE, a French company specialized in molecular diagnostics. ...